Gansane, Adama
Lingani, Moussa
Yeka, Adoke
Nahum, Alain
Bouyou-Akotet, Marielle
Mombo-Ngoma, Ghyslain
Kaguthi, Grace
Barceló, Catalina
Laurijssens, Bart
Cantalloube, Cathy
Macintyre, Fiona
Djeriou, Elhadj
Jessel, Andreas
Bejuit, Raphaël
Demarest, Helen
Marrast, Anne Claire
Debe, Siaka
Tinto, Halidou
Kibuuka, Afizi
Nahum, Diolinda
Mawili-Mboumba, Denise Patricia
Zoleko-Manego, Rella
Mugenya, Irene
Olewe, Frederick
Duparc, Stephan
Ogutu, Bernhards
Clinical trials referenced in this document:
Documents that mention this clinical trial
Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria
https://doi.org/10.1186/s12936-022-04420-2
Funding for this research was provided by:
Medicines for Malaria Venture
Article History
Received: 18 October 2022
Accepted: 16 December 2022
First Online: 3 January 2023
Declarations
:
: Ethical approval was provided by: Comité National d’Ethique pour la Recherche en Santé (CNERS), Cotonou, Benin; Comité d’Ethique pour la Recherche en Santé, Ouagadougou, Burkina Faso; Comité Institutionnel de Bioéthique (CIB) du CNRFP, Ouagadougou, Burkina Faso; Comité National d’Ethique pour la Recherche, Libreville, Gabon; Mulago Hospital Research and Ethics Committee, Kampala, Uganda; Kenya Medical Research Institute (KEMRI)—Scientific and Ethics Review Unit (SERU), Nairobi, Kenya.
: Consent for publication is not applicable.
: CB, FM, HD, SD, and ACM are employed by Medicines for Malaria Venture. BL is a consultant for Medicines for Malaria Venture and was paid for his work on this study. CC, ED, AJ, and RB are employed by Sanofi. AJ holds shares in the company. The other authors declare that they have no competing interests.